• LevelJump will issue up to 13,333,333 units at $0.15 per unit for gross proceeds of up to $2,000,000
  • Net proceeds from the financing will be used towards acquisitions and for general working capital purposes
  • The offering is expected to close in April
  • Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology
  • Shares in Leveljump Healthcare Corp. (JUMP) are unchanged on the day, trading at C$0.15 per share at 1:45 pm ET

LevelJump Healthcare (JUMP) will be conducting a non-brokered private placement for gross proceeds of up to $2,000,000.

The company will issue up to 13,333,333 units at $0.15 per unit. Each unit will consist of one common share and one common share purchase warrant.  Each warrant will entitle the holder to acquire one additional common share of Leveljump at an exercise price of $0.20 with an expiry date of March 31, 2024.

The net proceeds from the financing will be used towards acquisitions and for general working capital purposes.

The offering is expected to close in April.

Securities issued will be subject to a four-month hold period in accordance with applicable securities laws.

Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The company provides radiology solutions for hospitals, emergency rooms, and private clinics.

Shares in Leveljump Healthcare Corp. (JUMP) are unchanged on the day, trading at C$0.15 per share at 1:45 pm ET.

More From The Market Online

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.

PharmaTher evaluating 3D printing for personalized peptide medicines

PharmaTher is out to evaluate its GMP-ready 3D printing platform for producing personalized peptide medicines with customized doses.

Why biotech is outpacing the AI slump: 3 stocks to watch

The biotech sector is outperforming the broader market, shining a light on stocks best-positioned to address unmet patient needs.